ライフサイエンスコーパス: multiorgan

1 11 hearts, 1 kidney-pancreas, 5 lungs, and 5 multiorgans).

2 (range, 5-93) from liver (12), heart (4), or multiorgan (1) transplantation.

3 neurodegenerative epilepsy and results from multiorgan accumulations, termed Lafora bodies (LB), of

4 ng population that is experiencing long-term multiorgan adverse effects.

5 ne the tension between equity and utility in multiorgan allocation.

6 mmunohistochemistry was performed using both multiorgan- and in-house-constructed pancreatic tissue m

7 lant recipients (heart, lung, liver, kidney, multiorgan) at Hospital for Sick Children (2002-2011), e

8 lant recipients (heart, lung, liver, kidney, multiorgan) at The Hospital for Sick Children (2002-2011

9 ent susceptibility to infections, as well as multiorgan atopy and autoimmunity.

10 appab1(-/-)) develop lymphoproliferative and multiorgan autoimmune disease attributed in large part t

11 Importantly, these mice also develop a multiorgan autoimmune disease with autoantibodies agains

12 Surprisingly, we did not detect multiorgan autoimmune disease.

13 IgG4-RD is a multiorgan autoimmune disorder characterized by fibrous

14 -beta signaling (TGF-betaRIIDN mice) display multiorgan autoimmune disorders.

15 -Tgfbr2 KO mice die before 15 wk of age with multiorgan autoimmune inflammation and spontaneous activ

16 Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease.

17 ving lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic

18 w is necessary and sufficient to prevent the multiorgan autoimmunity characteristic of Aire-deficient

19 ral nervous system and is a component of the multiorgan autoimmunity syndrome that results from Aire

20 nrecognized role for NFkappaB1 in preventing multiorgan autoimmunity through its negative regulation

21 The patients displayed multiorgan autoimmunity, lymphoproliferation, and delaye

22 mmediate breakdown of tolerance and onset of multiorgan autoimmunity.

23 ciency in FOXP3(+) T cells results in lethal multiorgan autoimmunity.

24 dy deficiency, infection susceptibility, and multiorgan autoimmunity.

25 rance, and their deficiency results in fatal multiorgan autoimmunity.

26 Both humans and mice lacking Aire develop multiorgan autoimmunity.

27 ontrolling immune homeostasis and preventing multiorgan autoimmunity.

28 A patient with multiorgan autoinflammation, combined immunodeficiency,

29 yotonic dystrophy, as a robust suppressor of multiorgan breast cancer metastasis.

30 Despite the presence of multiorgan chronic inflammation, aged VISTA-deficient mi

31 ed disease (IgG4-RD) is a poorly understood, multiorgan, chronic inflammatory disease characterized b

32 Mutations in the ANKS6 gene cause multiorgan ciliopathies in humans, which include lateral

33 e, HIES) is a complex immune deficiency with multiorgan clinical manifestations and diverse genetic b

34 This amplifies multiorgan complications because BMSCs promote vascular

35 complex disease with cardiac involvement and multiorgan complications.

36 a significant NET burden contributing to the multiorgan damage.

37 These multiorgan defects are attenuated by platelet depletion

38 ll platelets in vivo markedly attenuates the multiorgan defects, suggesting that platelet lysosome se

39 l syndrome including embryonic lethality and multiorgan defects.

40 g demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that invol

41 Sepsis is a multiorgan disease affecting the ileum and jejunum (smal

42 Cystic fibrosis (CF) is a multiorgan disease caused by loss of a functional cystic

43 Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fib

44 n healthy individuals, HCMV can cause severe multiorgan disease in immunocompromised or immunonaive p

45 Alcohol dependence (AD) is a multiorgan disease in which excessive oxidative stress a

46 ultiorgan transplant, wherein a patient with multiorgan disease receives >1 organ from the same donor

47 VHL is a complex, multiorgan disease that spans the breadth of oncology su

48 in genes, resulting in chronic hemolysis and multiorgan disease that ultimately leads to premature de

49 rease in hospitalizations for pneumonia with multiorgan disease.

50 uberous sclerosis complex (TSC) is a genetic multiorgan disorder characterized by the development of

51 The patients had a multiorgan disorder that included congenital nephrotic s

52 s of functional alpha3beta1, causing a fatal multiorgan disorder.

53 tivity in human cell lines and virulence and multiorgan dissemination in mice.

54 el, safe, and inexpensive adjunct therapy in multiorgan donation.

55 rior to the procurement of other organs in a multiorgan donor and hence prior to cross-clamp.

56 eased donor uterus procurement in a deceased multiorgan donor setting.

57 Eighty-four multiorgan donors were randomly assigned to receive 80 m

58 hemical analysis in the exocrine pancreas of multiorgan donors with T1D (both at onset and at later s

59 er stages of the disease) and not in that of multiorgan donors with type 2 diabetes or nondiabetic do

60 al 0.51-0.9, p=.03) as well as patients with multiorgan dysfunction (odds ratio 0.78, 95% confidence

61 tatistically significant in patients who had multiorgan dysfunction (odds ratio 0.82, 95% confidence

62 chanism in several human diseases, including multiorgan dysfunction after either massive red blood ce

63 an lead to clinical complications, including multiorgan dysfunction and even death.

64 S-CoV) infection caused severe pneumonia and multiorgan dysfunction and had a higher crude fatality r

65 syndrome in children (MIS-C)-which comprises multiorgan dysfunction and systemic inflammation(2-13).

66 Sixty-seven percent of patients had multiorgan dysfunction at sepsis recognition, with 30% s

67 mited by side effects, including reversible, multiorgan dysfunction characterized by a cytokine-induc

68 resenting with fever, hyperinflammation, and multiorgan dysfunction frequently requiring intensive ca

69 Severe pneumonia and multiorgan dysfunction in COVID-19 and dengue haemorrhag

70 usion of aged stored blood may contribute to multiorgan dysfunction in susceptible patients.

71 Spleen rupture (3 cases) and multiorgan dysfunction syndrome (3 cases) were the secon

72 Sepsis patients with multiorgan dysfunction syndrome and/or shock (original s

73 le line disruption may still lead to sepsis, multiorgan dysfunction, and increased mortality.

74 ng cytokine-release syndrome with fevers and multiorgan dysfunction, CAR-T-cell-related encephalopath

75 The MELD-XI score, a marker of multiorgan dysfunction, is a promising risk stratifier i

76 ted for LT and was associated with increased multiorgan dysfunction, mechanical and vasopressor suppo

77 evalence, therapies used, new or progressive multiorgan dysfunction, ventilator- and vasoactive-free

78 ation to affect the development of shock and multiorgan dysfunction.

79 cific disorder resulting in hypertension and multiorgan dysfunction.

80 % subsequently developing new or progressive multiorgan dysfunction.

81 period leading to systemic inflammation and multiorgan dysfunction.

82 ritoneal cavity, reduced bacterial load, and multiorgan dysfunction.

83 flammation, cytopenias, and life-threatening multiorgan dysfunction.

84 nia, acute respiratory distress syndrome and multiorgan dysfunction.

85 l tissue damage and initiate and/or maintain multiorgan dysfunction.

86 esult in local angiotensin II generation and multiorgan dysfunctions.

87 ological state in which FGF23-alphaKlotho, a multiorgan endocrine network, is deranged in a self-ampl

88 The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and

89 % TBSA group; p<0.0001), 154 (16%) developed multiorgan failure (increasing from 6% [ten] in the 30-3

90 (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality.

91 Therefore, single-organ failure and/or multiorgan failure (MOF) are thought to contribute signi

92 ; 95% confidence interval: 1.26 to 1.30) and multiorgan failure (odds ratio: 2.23; 95% confidence int

93 d death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO p

94 was associated with increased postoperative multiorgan failure [42 (35%) vs 56 (20.4%), P = 0.001] a

95 e of UGIB in patients under AT are degree of multiorgan failure and comorbidity, but not AT itself.

96 syndrome (SIRS) and the events that lead to multiorgan failure and death are poorly understood.

97 s caused by large-scale trauma that leads to multiorgan failure and death, despite the stemming of bl

98 sease with elevated inflammatory biomarkers, multiorgan failure and death.

99 y mechanical circulatory support may prevent multiorgan failure and death.

100 ukopenia, and thrombocytopenia and developed multiorgan failure and hemorrhage.

101 s of severe COVID-19 and are associated with multiorgan failure and increased mortality.

102 anada, the United States, and Europe who had multiorgan failure and were receiving mechanical ventila

103 patients with hyperinflammation and evolving multiorgan failure at risk of developing dengue-HLH.

104 CSA was greater in patients who experienced multiorgan failure by day 7 (-15.7%; 95% CI, -27.7% to 1

105 an progress to respiratory failure, although multiorgan failure can also occur.

106 illness and was more severe among those with multiorgan failure compared with single organ failure.

107 ectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 eve

108 sis with rapidly progressive myocarditis and multiorgan failure from Ehrlichia chaffeensis in a previ

109 diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV-8.

110 been a steady increase in the prevalence of multiorgan failure in AMI-CS.

111 y also promote intravascular coagulation and multiorgan failure in animal models.

112 There are limited data on acute noncardiac multiorgan failure in cardiogenic shock complicating acu

113 d lethal hemorrhagic fever with bleeding and multiorgan failure in human patients.

114 ential for neurological recovery and ongoing multiorgan failure is warranted for prognostication and

115 risk for systemic sepsis and, in some cases, multiorgan failure leading to death.

116 ntation as telomeropathy in adults, in which multiorgan failure may be prominent.

117 ochondrial dysfunction can occur and lead to multiorgan failure or death.

118 mphohistiocytosis and has been attributed to multiorgan failure or the use of nephrotoxic drugs, but

119 le patient with liver failure also developed multiorgan failure requiring vasopressors, hemodialysis,

120 e to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in ind

121 94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload.

122 Hemolytic diseases are frequently linked to multiorgan failure subsequent to vascular damage.

123 rstitial lung disease and one as a result of multiorgan failure that occurred in the context of infec

124 systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly document the diagnosis and

125 Presence of multiorgan failure was independently associated with hig

126 ,253 AMI-CS admissions, noncardiac single or multiorgan failure was noted in 32.4% and 31.9%, respect

127 Multiorgan failure was seen more commonly in admissions

128 ular nature, respiratory origin, sepsis, and multiorgan failure were significantly lower in beta-bloc

129 m sinusoidal obstruction syndrome-associated multiorgan failure with Candida sepsis on day +40 follow

130 e of myocarditis, and one patient because of multiorgan failure with Guillain-Barre syndrome.

131 , coagulation abnormalities, hemorrhage, and multiorgan failure with up to 33% case fatality rates (C

132 nvestigator (pneumonia, and septic shock and multiorgan failure).

133 ions (eg, bacteraemia, metastatic infection, multiorgan failure, acute respiratory distress syndrome,

134 slocates to the bloodstream, causing sepsis, multiorgan failure, and death.

135 failure, central nervous system involvement, multiorgan failure, and other manifestations.

136 r Charlson comorbidity index, and those with multiorgan failure, and similar in males and females.

137 organ damage, such as acute chest syndrome, multiorgan failure, and sudden death.

138 vasopressors, which results in hypotension, multiorgan failure, and ultimately patient death.

139 verse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related.

140 ing failure, respiratory infections, sepsis, multiorgan failure, durations of stay in the ICU and hos

141 y failure, respiratory infection, sepsis and multiorgan failure, ICU and hospital length of stay and

142 emed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all

143 leeding, need for renal replacement therapy, multiorgan failure, stroke or transient ischemic attack,

144 disseminated intravascular coagulation, and multiorgan failure, which all carry poor prognoses.

145 stroke causing death, and 1 death following multiorgan failure.

146 to a rapidly fatal meningoencephalitis with multiorgan failure.

147 nt-related death secondary to sepsis-induced multiorgan failure.

148 ignancy, and severe cutaneous reactions with multiorgan failure.

149 scular complications that ultimately promote multiorgan failure.

150 atic disorder leading to heart, and possibly multiorgan failure.

151 opposed, may result in tissue damage or even multiorgan failure.

152 ts/microL and albuminemia <35 g/L) died from multiorgan failure.

153 t who had a combination of syndromes died of multiorgan failure.

154 own origin, complicated by septic shock with multiorgan failure.

155 mortality among critically ill patients with multiorgan failure.

156 AMI VSR is advisable before establishment of multiorgan failure.

157 he patient with single LuTX died from septic multiorgan failure.

158 8 months, with 7 deaths caused by cardiac or multiorgan failure.

159 nd could be responsible for septic shock and multiorgan failure.

160 tant clinical outcomes, such as mortality or multiorgan failure.

161 iated with infection, hepatotoxicity, and/or multiorgan failure.

162 increasing acute phase reactants tests, and multiorgan failure.

163 teremia, systemic inflammatory response, and multiorgan failure.

164 e release rapidly leading to respiratory and multiorgan failure.

165 ia, acute respiratory distress syndrome, and multiorgan failure.

166 ectrum antibiotics, she ultimately died from multiorgan failure.

167 similarly effective (AUC 0.85) at predicting multiorgan failure.

168 ady increase in the prevalence of single and multiorgan failure.

169 hondrial and cellular dysfunction leading to multiorgan failure.

170 f cardiac function and the patient developed multiorgan failure.

171 nd consequently vascular leakage, shock, and multiorgan failure.

172 cularization were performed less commonly in multiorgan failure.

173 e control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansi

174 hancing myofibroblast generation, leading to multiorgan fibrosis and cardiac dysfunction in mice duri

175 ft-versus-host disease (cGVHD), resulting in multiorgan fibrosis and diminished function.

176 for modulating TGF-beta signaling to reduce multiorgan fibrosis during aging and fibrosis-associated

177 hereas truncating mutations are found in the multiorgan form of Fraser syndrome.

178 al markers of patient recovery, for example, multiorgan function, infections, sepsis, and length of s

179 Tuberous sclerosis complex (TSC) is a multiorgan genetic disease in which brain involvement ca

180 By using multiorgan genome-wide analysis of aged mice, we found t

181 ical failure were used to identify single or multiorgan (>=2 organ systems) noncardiac organ failure.

182 autosomal dominant disease characterized by multiorgan hamartomas, including renal angiomyolipomas a

183 r 79% of combat-related injuries, leading to multiorgan hemorrhage and uncontrolled bleeding.

184 When tested in a model of blast trauma with multiorgan hemorrhaging, i.v. administration of the hemo

185 e apply mass spectrometry to a sophisticated multiorgan human-on-a-chip system for the comprehensive

186 ominant plasmablast clones of a patient with multiorgan IgG(4)-RD stained human pancreatic tissue sec

187 A man in his mid-50s with multiorgan IgG4-RD developed progressive spastic hemipar

188 Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident

189 While low-dose SMN-ASO rescues multiorgan impairment, additional NCALD reduction signif

190 These Tgfb1(C33S/C33S) mice develop multiorgan inflammation and tumors consistent with reduc

191 levels of IFN-gamma resulted in progressive multiorgan inflammation and two copies of the mutant all

192 are deficient in Tregs and succumb to severe multiorgan inflammation by 4 weeks of age.

193 inosine itself prolonged life and inhibited multiorgan inflammation by reducing Th1/Th2 cells and th

194 illus reuteri prolonged survival and reduced multiorgan inflammation in SF mice.

195 ent cpdm mice, which develop severe skin and multiorgan inflammation that has been hypothesized to be

196 ative dermatitis mutation (Cpdm) mice causes multiorgan inflammation, yet this phenotype is not trans

197 se phenotype characterized by itchy skin and multiorgan inflammation.

198 a broad spectrum of autoantibodies and fatal multiorgan inflammation.

199 emic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated w

200 symptoms (DiHS/DRESS) is a potentially fatal multiorgan inflammatory disease associated with herpesvi

201 3 regulatory T cells and suffer from a fatal multiorgan inflammatory disease.

202 The multiorgan inflammatory diseases associated with symptom

203 e dermatitis in mice (cpdm) is a spontaneous multiorgan inflammatory disorder with pathological hallm

204 rprisingly, Malt1(PD/PD) animals developed a multiorgan inflammatory pathology, characterized by Th1

205 reduced regulatory T cells and a progressive multiorgan inflammatory pathology.

206 which SARS-CoV-2 induces the multisystem and multiorgan inflammatory responses that, collectively, co

207 l source of proinflammatory mediators drives multiorgan injury in response to AKI.

208 ents who had high-risk TA-TMA (hrTA-TMA) and multiorgan injury treated with the complement blocker ec

209 endothelial dysfunction that can progress to multiorgan injury, and severe cases are associated with

210 AKI) is frequently complicated by extrarenal multiorgan injury, including intestinal and hepatic dysf

211 iated with adverse cardiovascular events and multiorgan injury.

212 nt role of TGF-beta1 signaling in modulating multiorgan injury.

213 and people with obesity who were matched on multiorgan insulin sensitivity (inhibition of adipose ti

214 issue and liver fat content, and it improves multiorgan insulin sensitivity and beta-cell function (i

215 Multiorgan insulin sensitivity before and after treatmen

216 atment markedly improved several measures of multiorgan insulin sensitivity, adipose tissue inflammat

217 Body composition, multiorgan insulin sensitivity, VLDL apolipoprotein B100

218 to capture complex human physiology and the multiorgan interactions; the results we present here cou

219 FF per patient correlated with the degree of multiorgan involvement (P = .014).

220 osis (ATTR) is a heterogeneous disorder with multiorgan involvement and a genetic or nongenetic basis

221 eveloped a lethal inflammatory disorder with multiorgan involvement and autoantibody production mimic

222 sistant nephrotic syndrome (SRNS) as part of multiorgan involvement but may also contribute to isolat

223 Multiorgan involvement is common.

224 Patient history, gene mutation, and multiorgan involvement were obtained from clinical recor

225 As JS is associated with multiorgan involvement, these patients should enter a di

226 re severe adverse drug-induced reaction with multiorgan involvement.

227 er patient was correlated with the degree of multiorgan involvement.

228 st as a viral-induced hyperinflammation with multiorgan involvement.

229 was significantly lower among patients with multiorgan involvement.

230 ed with TSC gene mutations and with brain or multiorgan involvement; their number per patient was cor

231 dministration of an A2AR agonist will reduce multiorgan IRI in a porcine model of ECPR.

232 This microvascular thrombosis causes multiorgan ischemia with potentially life-threatening co

233 ubiquitin ligase Itch in mice caused massive multiorgan lymphocyte infiltration and skin lesions, chr

234 at the initial stages of the process involve multiorgan metabolic interactions that produce a systemi

235 se concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progres

236 bly, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in

237 xorubicin treatment partially suppressed the multiorgan metastasis of 4T1 breast cancer cells in the

238 ocess in the fatty liver that contributes to multiorgan morbidity.

239 severe pan-nephritis, and/or severe systemic multiorgan necrotizing inflammation.

240 rapy, pancreaticogastrostomy reconstruction, multiorgan or vascular resection, and elevated operative

241 nce was associated with brain (P = .011) and multiorgan (P = .008) involvement.

242 ts in growth retardation, eye malformations, multiorgan pathologies, vascular defects, and neonatal d

243 cohort (n = 232; 20.2%) with an unfavorable multiorgan phenotype across all 3 anatomic axes as compa

244 community cohort, identifies an unfavorable multiorgan phenotype associated with adverse health outc

245 3 anatomic axes as compared with a favorable multiorgan phenotype.

246 stic importance of computed tomography-based multiorgan phenotypes associated with adverse health out

247 Cystic fibrosis (CF) is a multiorgan recessive genetic disease caused by mutations

248 Current allocation schemes give priority to multiorgan recipients compared with single-organ transpl

249 + individuals was more likely to occur among multiorgan recipients, and there was a tendency for poor

250 hese mice, and provide practical examples of multiorgan response to drugs that modulate CMA.

251 with multiple cGVHD organ involvement had a multiorgan response.

252 n-on-a-chip systems being designed to assess multiorgan responses to compounds.

253 iver, n = 283; heart, n = 218; lung, n = 36; multiorgan/small bowel, n = 14) were compared with 5.3 m

254 treatment of the precipitant while providing multiorgan-supportive care that addresses the complex pa

255 Clinically, chronic GVHD is a pleiotropic, multiorgan syndrome involving tissue inflammation and fi

256 for this variant but are not affected by the multiorgan syndromes noted in the proband.

257 HD1 Notably, when mutated, these genes cause multiorgan syndromes that may include CAKUT as a feature

258 A multiorgan syndromic disorder characterized by siderobla

259 d immunoglobulin deposition are required for multiorgan system cGVHD and associated bronchiolitis obl

260 rodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar o

261 ompatibility complex (MHC) mismatch model of multiorgan system cGVHD with bronchiolitis obliterans sy

262 s required for cGVHD in a nonsclerodermatous multiorgan system disease model that includes bronchioli

263 graft-versus-host-disease (cGVHD) can cause multiorgan system disease, typically with autoimmune-lik

264 Sepsis is characterized by multiorgan system dysfunction that occurs because of inf

265 MPs may contribute to the multiorgan system failure and high mortality of ALF.

266 c shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contribu

267 The host injury involved in multiorgan system failure during severe inflammation is

268 Hepa Wash was a safe procedure and improved multiorgan system failure in pigs with ALF.

269 propriately resourced facilities, to prevent multiorgan system failure, and to tailor disease-specifi

270 Secondary outcomes, including multiorgan system failure, packed red blood cell transfu

271 rdiogenic shock, ventricular arrhythmias, or multiorgan system failure.

272 or reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans a

273 e frequently associated with polydactyly and multiorgan system involvement.

274 nor T cells reduced active chronic GVHD in a multiorgan system model of bronchiolitis obliterans (BO)

275 histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cell responses

276 In a murine model of multiorgan system, nonsclerodermatous disease with bronc

277 ntial for use as a structural technique in a multiorgan system.

278 iving rise to metabolites that contribute to multiorgan/system damage and immunosuppression.

279 lls (Tregs) essential for protection against multiorgan systemic autoimmunity.

280 cognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged i

281 egulator transcription factor, which develop multiorgan T cell-mediated autoimmunity.

282 ion in B cells and with age developed severe multiorgan tissue inflammation.

283 medication-related complications, including multiorgan toxicities and systemic side effects.

284 ered systemically and carry inherent risk of multiorgan toxicities.

285 ood cell (WBC) transcriptome to the general, multiorgan transcriptome.

286 Multiorgan transcriptomics demonstrates broad HPA axis t

287 with other races: HR, 1.45-2.04; P < 0.001), multiorgan transplant (HR, 1.35; P < 0.001), previous ma

288 In a prior multiorgan transplant database study, recipient Epstein-

289 Banff conference describes the creation of a multiorgan transplant gene panel by the Banff Molecular

290 Multiorgan transplant patients accounted for 25% of PTLD

291 liver and kidney (SLK) transplant, a type of multiorgan transplant, as a case study to examine the te

292 disease have led to an increasing demand for multiorgan transplant, wherein a patient with multiorgan

293 Multiorgan transplantation allocation may not be congrue

294 United Network for Organ Sharing multiorgan transplantation allocation policy allows sequ

295 ith pretransplantation diabetes mellitus and multiorgan transplantation were excluded.

296 Multiorgan transplantations, split grafts, or non-heart-

297 Multiorgan transplants and patients with >2 total LTs we

298 models are identified, and single-organ and multiorgan transplants are defined, then each risk adjus

299 Recipients of lung or multiorgan transplants were at highest risk.

300 phenolate immunosuppression and did not have multiorgan transplants.